Actinium Pharmaceuticals, Inc. (ATNM) stock
ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/3079% below fair value
$1.64+0.05 (+3.14%)
Close on Nov 13, 2026Market cap $51.56MP/E 4.6Yield –
Actinium Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Actinium Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was $9.78M. For fiscal 2025 it was -$36.07M. The highest annual figure on record is -$3.28M in fiscal 2011.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$36.07M | – |
| FY2024 | Dec 31, 2024 | -$41.92M | – |
| FY2023 | Dec 31, 2023 | -$51.71M | – |
| FY2022 | Dec 31, 2022 | -$33.41M | – |
| FY2021 | Dec 31, 2021 | -$24.44M | – |
| FY2020 | Dec 31, 2020 | -$21.95M | – |
| FY2019 | Dec 31, 2019 | -$21.65M | – |
| FY2018 | Dec 31, 2018 | -$23.78M | – |
| FY2016 | Dec 31, 2016 | -$26.77M | – |
| FY2015 | Dec 31, 2015 | -$24.78M | – |
| FY2014 | Dec 31, 2014 | -$22.44M | – |
| FY2013 | Dec 31, 2013 | -$6.59M | – |
| FY2012 | Dec 31, 2012 | -$7.95M | – |
| FY2011 | Dec 31, 2011 | -$3.28M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $28.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.87M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.86M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.14M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.92M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.40M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.38M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.73M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.43M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.40M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.67M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.03M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.91M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.34M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.95M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.25M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.32M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.55M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.58M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.53M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.55M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.98M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.60M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.35M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.18M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.90M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.34M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.68M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.19M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.78M | – |
| Q4 FY2016 | Dec 31, 2016 | -$6.81M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.08M | – |
See a number that looks wrong?